I-MAB Transitions to NovaBridge Biosciences with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform Life Science Investing
AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib in Adults and Adolescents with Vitiligo Pharmaceutical Investing
Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative Control Group Life Science Investing
Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy Life Science Investing
U.S. Centers for Medicare & Medicaid Services finalizes National Coverage Determination for the Medtronic Symplicity Spyral renal denervation system Medical Device Investing
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets Life Science Investing
Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 Life Science Investing
